Company: LIDRW
Filing Date: 2025-08-11
Form Type: S-3
Source: 0000947871-25-000731
Chunk: 2

Company: AEye, Inc.
Filing Date: 2025-08-11
Form: S-3
Chunk 2
---
 Delaware limited liability company (the “Selling Stockholder” or “IGEP”) of up to 350,000 shares of common
stock of AEye, Inc., par value $0.0001 per share (the “Common Stock”), issuable to the Selling Stockholder upon exercise of
the warrant to purchase common stock (the “Warrant”). The Warrant was issued to the Selling Stockholder pursuant to the terms
of the Warrants Agreement, dated May, 23, 2025, by and between AEye, Inc. and the Selling Stockholder (the “Warrant Agreement”),
which was entered in connection with the settlement agreement between AEye, Inc., its subsidiary AEye Technologies, Inc., and the Selling
Stockholder, dated April 28, 2025. The Warrant has an exercise price of $2.22.

We are not selling any securities under this prospectus and will
not receive any of the proceeds from the sale of our Common Stock by the Selling Stockholder. However, we may receive proceeds from the
exercise of the Warrant, if any portion of the Warrant is exercised in cash. We intend to use those proceeds, if any, for working capital
or general corporate purposes. For more information, see “Use of Proceeds.”

The Selling Stockholder may sell all or a portion
of the shares of our Common Stock beneficially owned by them and included in this prospectus in a number of different ways and at varying
prices. We provide more information about how the Selling Stockholder may sell the shares in the section entitled “Plan of Distribution.”

The Selling Stockholder may sell the securities directly
to or through underwriters or dealers, and also to other purchasers or through agents on a continuous or delayed basis. The names of any
underwriters or agents that are included in a sale of securities, and any applicable commissions or discounts, will be stated in any accompanying
prospectus supplement.

The Selling Stockholder will pay all sales and brokerage
commissions and similar expenses in connection with the offer and resale of the Common Stock by the Selling Stockholder pursuant to this
prospectus. We will pay the expenses (except sales and brokerage commissions and similar expenses) incurred in registering under the Securities
Act of 1933, as amended, the offer and resale of the shares included in this prospectus, including legal and accounting fees. See “Plan of Distribution.”

We are an “emerging growth company” as defined in Section
2(a